Takeda Pharmaceutical Co Ltd 2021 IR
The report outlines Takeda's financial and non-financial performance for the fiscal year ended March 31, 2021, highlighting its progress as a global, values-based, R&D-driven biopharmaceutical company. Key achievements include achieving carbon neutrality across its value chain for FY2019 emissions and progressing 11 new molecular entities in its Wave 1 pipeline. Takeda also expanded its global vaccine collaborations to support the COVID-19 response, including partnerships with Novavax and Moderna in Japan. Additionally, the company advanced its diversity, equity, and inclusion initiatives, with women comprising 52% of its global workforce.
Company: Takeda Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2021
Type: IR
Pages: 101
Takeda Pharmaceutical Co Ltd
Annual Integrated Report
The report outlines Takeda's financial and non-financial performance for the fiscal year ended March 31, 2021, highlighting its progress as a global, values-based, R&D-driven biopharmaceutical company. Key achievements include achieving carbon neutrality across its value chain for FY2019 emissions and progressing 11 new molecular entities in its Wave 1 pipeline. Takeda also expanded its global vaccine collaborations to support the COVID-19 response, including partnerships with Novavax and Moderna in Japan. Additionally, the company advanced its diversity, equity, and inclusion initiatives, with women comprising 52% of its global workforce.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women in Management
Net Zero Target
Employees